Androgens and male aging: current evidence of safety and efficacy by Gooren, L.J.G.
136
Asian Journal of Andrology  |  http://www.asiaandro.com;  aja@sibs.ac.cn 
npg
Androgens and male aging: current evidence of safety and efficacy
Louis J. Gooren
Department of Endocrinology, VU University Medical Center, Amsterdam 1007 MB, the Netherlands
Correspondence to: Prof. Louis J. Gooren, Department of Endo-
crinology, VU University Medical Center, P.O. Box 7057, Amster-
dam 1007 MB, the Netherlands.
Present address: 72/1 moo1, T.Palan, A.Doisaket, Chiang Mai 
50220, Thailand.
Fax: +66-5334-7742                 E-mail: louisjgooren@gmail.com
Received: 13 January 2010      Revised: 24 January 2010
Accepted: 27 January 2010      Published online: 15 February 2010
Review
Asian Journal of Andrology (2010) 12: 136–151
© 2010 AJA, SIMM & SJTU  All rights reserved 1008-682X/09 $ 32.00
www.nature.com/aja
Abstract
Many signs of aging, such as sexual dysfunction, visceral obesity, impaired bone and muscle strength, bear 
a close resemblance to features of hypogonadism in younger men.  The statistical decline of serum testosterone 
in aging men is solidly documented.  It has been presumed that the above features of aging are related to the 
concurrent decline of androgens, and that correction of the lower-than-normal circulating levels of testosterone will 
lead to improvement of symptoms of aging.  But in essence, the pivotal question whether the age-related decline 
of testosterone must be viewed as hypogonadism, in the best case reversed by testosterone treatment, has not been 
definitively resolved.  Studies in elderly men with lower-than-normal testosterone report improvement of features of 
the metabolic syndrome, bone mineral density, of mood and of sexual functioning.  But as yet there is no definitive 
proof of the beneficial effects of restoring testosterone levels to normal in elderly men on clinical parameters.  Few 
of these studies meet as yet rigorous standards of scientific enquiry: double-blind, placebo-controlled design of the 
study.  The above applies also to the assessment of safety of testosterone administration to elderly men.  There is so 
far no convincing evidence that testosterone is a main factor in the development of prostate cancer in elderly men 
and guidelines for monitoring the development of prostate disease have been developed.  It is of note that there are 
presently no long-term safety data with regard to the prostate.  Polycythemia is another potential complication of 
testosterone treatment.  It is dose dependent and can be managed with dose adjustment.
Asian Journal of Andrology (2010) 12: 136–151.  doi: 10.1038/aja.2010.4; published online 15 February 2010.  
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1 Introduction
When Prof. Alex Vermeulen from Gent/Belgium 
in the 1970s started his pioneering work on the decline 
of testosterone levels in aging men, his work seemed 
to most professionals only of theoretical interest  (for 
review:[1]). But further studies have substantiated 
that, with age, a significant percentage of men over 
the age of 60 years have serum testosterone levels 
below the lower limits of normal for young adult 
men (aged 20–30 years) [2, 3].  Now, 30–40 years 
later, the pathophysiological implications of this 
decline, sometimes amounting to outright testosterone 
deficiency, have become clearer. 
Until a decade ago the ailments of elderly men, 
such as atherosclerosis, hypertension, diabetes mellitus, 
lower urinary tract symptoms and erectile dysfunction 
(ED), were regarded as distinct diagnostic/therapeutic 
entities but there is a growing evidence that these 
entities are not disparate and, to improve the health of 
the aging male, require an integral approach. There is 
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an interdependence between the metabolic syndrome, 
ED and patterns of testosterone in aging men [4, 5]. 
The main features of the metabolic syndrome are 
abdominal obesity, insulin resistance, hypertension 
and dyslipidemia, significant factors in the etiology of 
erectile functions. The metabolic syndrome is associated 
with lower-than-normal testosterone levels [6, 7]. 
Testosterone is a determinant of glucose homeostasis 
and lipid metabolism [8] and plays also a significant 
role in the development and maintenance  of bone 
and muscle mass.  Testosterone is not only a factor in 
libido but exerts also essential effects on the anatomical 
and physiological substrate of penile erection [9]. The 
effects of phosphodiesterase type 5 (PDE5)-inhibitors 
are suboptimal in the presence of hypogonadal values 
of circulating testosterone [9].  A relationship between 
lower urinary tact symptoms (LUTS) and circulating 
levels of testosterone has been difficult to prove but 
the association of LUTS with the metabolic syndrome 
and with ED is well established in the literature [10]. 
Testosterone treatment of hypogonadal not only 
improves features of the metabolic syndrome but also 
improves LUTS [11].  With these recent insights, the 
health problems of elderly men must be placed in a 
context that allows an integral approach.  On the basis 
of recent insights, diagnosis of testosterone deficiency 
should be part of the diagnostic work-up of the above 
conditions. 
2 Late onset hypogonadism (LOH) vs. classical 
hypogonadism
Many signs and symptoms of aging, such as 
sexual dysfunction, visceral obesity, impaired bone 
and muscle strength, mood disturbances bear a close 
resemblance to features of hypogonadism in younger 
men.  In younger men improvement of the symptoms 
of hypogonadism upon testosterone replacement has 
been convincingly proven.  Presently, the statistical 
decline of serum testosterone in aging men is solidly 
documented [1, 3].  So, it is tempting to associate the 
above described features of aging to the concurrent 
decline of androgen action in the elderly, and to assume 
that correction of the lower-than-normal circulating 
levels of testosterone will lead to improvement of signs 
and symptoms of aging.  But in essence, the pivotal 
question whether the age-related decline of testosterone 
must be viewed as hypogonadism, i.e. a deficiency 
of testosterone manifesting itself with clinical signs 
and symptoms of insufficient androgen action, and 
in the best case reversed by testosterone treatment, 
has not been definitively resolved.  This point has 
been eloquently made in a paper by Handelsman and 
Liu [12], cautioning against a too facile prescription 
of testosterone to aging men in the hope to improve, 
or even reverse, signs and symptoms of aging.  The 
authors argue for well-designed, placebo-controlled 
double-blind studies documenting unequivocally the 
benefits of restoring testosterone levels in elderly men 
to the normal range while also closely monitoring 
the risks of testosterone administration to aging men. 
The present studies trying to prove the point have a 
less-than-optimal design (not blinded, not placebo-
controlled) and understandably, in the time frame of 
the study, usually document surrogate markers of a 
disease and not clinical endpoints.  For instance, do 
men whose features of the metabolic syndrome improve 
upon testosterone treatment, have a lower risk of type 2 
diabetes mellitus and cardiovascular disease?  Even 
more difficult to prove over a relatively short period of 
a clinical study: do men whose bone mineral density 
(BMD) improves upon testosterone treatment have a 
reduction in fracture rate?  To document such an effect, 
long-term studies are needed.
3	 Who	is	truly	testosterone-deficient	in	old	age?
As indicated above, circulating levels of testos-
terone decline with aging. The vast majority of men 
will have circulating testosterone values which are 5%–
20% below reference values for men.  And it has been 
difficult to draw a clear dividing line between blood 
levels of testosterone which represent a hypogonadal 
and a eugonadal state. In addition, blood testosterone 
thresholds for androgen deficiency symptoms are 
highly consistent within a person but differ between 
people [13].  Hypogonadal men who receive androgen 
treatment perceive the threshold for androgen deficiency 
symptoms at highly reproducible blood testosterone 
levels.  This distinctively individual trigger level for 
androgen deficiency symptoms differs, however, widely 
between men.  The threshold varies from very low to 
values above the lower limit of the eugonadal reference 
range.  On average it approximates the lower limit of 
the eugonadal reference range for young men [13]. 
The factors which define this symptomatic threshold 
are as yet unknown but it is reasonable to assume 
that genetic polymorphisms of the androgen receptor 
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influencing androgen sensitivity play a significant 
role [14, 15].  The impact of the aging process and 
acquired chronic disease with aging on the threshold for 
androgen deficiency symptoms are presently uncharted 
territory [13].  Another issue is whether an age-specific 
reference range of testosterone values is appropriate 
for diagnosing testosterone deficiency in old age.  Most 
population studies show that obesity and/or disease 
and lifestyle has a profound impact on values of 
testosterone [16, 17].  There is as present no published 
evidence that use of age-appropriate reference values 
offers advantages over use of reference values of the 
general population but it is an important point in the 
conceptualization of the desirability of testosterone 
treatment of elderly men. 
4 Thresholds and dose-response relationships of 
androgen effects
The concept of threshold values of circulating 
testosterone for manifestation of androgen deficiency 
symptoms, is only beginning to be supported by 
empirical evidence.  A couple of s tudies have 
suggested a threshold for androgen effects on male 
sexual function, primarily libido, becoming evident 
at the lower range of reference values of blood 
testosterone concentrations [18, 19].  These studies 
were, however, not able to define explicitly such a 
threshold.  Conversely, muscle appears to exhibit 
linear dose-response relationship to testosterone from 
below to above the eugonadal reference range for 
blood testosterone concentrations [20].  One study has 
suggested a dose-response relationship for effects of 
normalization of circulating testosterone on features 
of the metabolic syndrome [21], but an optimal range 
for those beneficial effects was not established in this 
study.  Whether linear dose-response or threshold 
models apply to other androgen-sensitive tissues, such 
as bone and prostate, psychosexual and cardiovascular 
effects remains to be determined.  So, from recent 
studies of elderly men it has become apparent that 
spectrum of complaints of testosterone deficiency 
cannot be related to a specific threshold of testosterone 
concentrations, but that thresholds vary with the various 
symptoms of testosterone deficiency [22].  In a cohort 
of men androgen-related loss of libido or vigor became 
more prevalent when testosterone concentrations 
fell below [15] nmol per liter, while depression and 
diabetes mellitus type 2 (also in nonobese men) were 
significantly more present in men with testosterone 
concentrations below 10 nmol L-1.  Symptoms related to 
androgen deficiency in this study could be subdivided 
in three independent groups: psychosomatic complaints, 
metabolic disorders, and sexual health problems. 
Patients suffering from one of these three groups 
exhibit distinct features in terms of androgen levels, 
age, and body mass index.  So, complaints are not only 
linked to androgen levels but age and body mass index 
carried weight as well in the manifestation of signs 
and symptoms of androgen deficiency [22].  To further 
complicate the matter of the relationship between 
testosterone levels on the one hand and symptoms of 
testosterone deficiency on the other, the authors have 
drawn attention to the multifactorial impact on certain 
androgen-related functions [22].  ED may serve as an 
example of a composite dysfunctionality in which, apart 
from testosterone concentrations, arterial endothelial 
function, neuronal integrity and psychological factors 
play pivotal roles [23, 24], almost precluding the 
establishment of a straightforward relationship between 
testosterone levels and erectile dysfunction. In the 
study of Zitzmann et al. [22] ED was identified as a 
composite pathology of metabolic risk factors, smoking, 
and depression, and only testosterone concentrations 
below 8 nmol L-1 contributed to that symptom. So, 
the various symptoms of LOH might start at various 
circulating concentrations of androgens.  With a given 
plasma testosterone level, some complaints might be 
present and others not.  This has also been confirmed in 
other studies establishing symptom-specific thresholds 
of androgen levels [1, 2, 25–27].  It, therefore, comes 
as no surprise that there is a significant variation among 
clinics and European countries in their application 
of threshold values of testosterone s ignifying 
hypogonadism which range from 7.5 to 12.0 nmol L-1 
[28].  Almost certainly a factor in this observation is 
that physicians in different countries will have different 
concepts of what constitute the core symptoms of 
hypogonadism.  On the basis of the above observations 
it is clear that the symptoms of testosterone deficiency 
are not uniformly and predictably related to values 
of blood testosterone, which may lead to different 
diagnostic criteria for testosterone deficiency.  So, 
the conclusion seems inevitable that the clinical 
manifestations of hypogonadism are multifactorially 
determined and that the diagnosis should not only 
depend on the measurement of testosterone but proper 
assessment should comprise somatic and psychological 
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aspects in addition to measurement of testosterone [29].
5 Diagnosis of LOH
The diagnosis of LOH and, certainly, the decision 
to provide androgen treatment must be made with 
caution, taking the specific increment of symptom 
prevalence in relation to testosterone levels into account. 
The above being the case, it is virtually impossible to 
take a blood testosterone value as a sole indication 
for testosterone treatment.  The presenting symptom 
of hypogonadism in a man may or may not be related 
to that testosterone value, though the lower the value 
of blood testosterone, the greater the likelihood.  A 
decision to provide androgen treatment must not only 
be guided by the levels of blood testosterone but, 
based on clinical judgment, more the likelihood that 
symptoms are related to that particular testosterone 
level.  The decision to treat will have an element of 
arbitrariness unless testosterone is truly low (< 6 nmol 
L-1) or truly in the normal range (> 15 nmol L-1).  A case 
can be made for a therapeutic trial of testosterone if the 
interpretation of clinical and laboratory data provide 
an ambiguous outcome [30, 31].  In case of sexual 
dysfunction this approach was helpful in treating the 
disorder [32].
In summary, physicians have to be aware that 
testosterone plays a significant but not all-decisive 
role in older male patients and that replacement 
options should be based on symptoms and on hormone 
concentrations, which should be evaluated on a 
symptom-specific basis.  Physicians treating elderly 
men should have expertise in the signs and symptoms 
of testosterone deficiency which have a broad spectrum 
of psychological, metabolic and sexual symptoms. 
Naturally, testosterone is not a panacea of the all the 
mental and somatic problems men encounter in the 
process of aging, and indiscriminate use in men who 
present with vague symptoms will have many failures. 
In patients at risk or suspected of hypogonadism, 
a thorough physical and biochemical work-up is 
necessary.  Transient decreases of serum testosterone 
levels such as those due to acute illnesses should be 
excluded by careful clinical evaluations and repeated 
hormone measurement.  Hypogonadism (primary or 
secondary) can occur at all ages including elderly 
men.  Risk factors for hypogonadism in older men may 
include chronic illnesses (including diabetes mellitus, 
chronic obstructive lung disease, inflammatory arthritic 
disease, renal disease, and HIV-related disease), obesity, 
metabolic syndrome, and hemochromatosis.  A serum 
sample for total testosterone determination should be 
obtained between 07:00 and 11:00 hours. The most 
widely accepted parameters to establish the presence 
of hypogonadism is the measurement of serum total 
testosterone.  There are no generally accepted lower 
l imi ts of normal .  There is , however, general 
agreement that the total testosterone level above 
12 nmol L-1 (350 ng dL-1) does not require substitution. 
Similarly, based on the data of younger men, there is 
consensus that patients with serum total testosterone 
levels below 8 nmol L-1 (230 ng dL-1) will usually 
benefit from testosterone treatment.  If the serum 
total testosterone level is between 8 and 12 nmol L-1, 
repeating the measurement of total testosterone with 
sex hormone-binding globulin (SHBG) to calculate free 
testosterone or free testosterone by equilibrium dialysis 
may be helpful.  Measurements of serum luteinizing 
hormone will assist in differentiating between primary 
and secondary hypogonadism and serum prolactin 
is indicated when the serum testosterone is lower 
than 5.2 nmol L-1 (150 ng dL-1) or when secondary 
hypogonadism is suspected.  Since there are known 
variations between assay methods, it is imperative that 
the practitioners utilize reliable laboratories and are 
acquainted with the reference ranges for testosterone 
from their local laboratory [31].  Current immunometric 
methods for the measurement of testosterone can 
distinguish between hypogonadism and normal 
adult men.  However, the methods based on mass 
spectrometry are more accurate and precise [31], and 
are increasingly recognized as the method of choice for 
serum testosterone measurement.  The measurement of 
free or bioavailable testosterone should be considered 
when the serum total testosterone concentration is not 
diagnostic of hypogonadism, particularly in obese 
men or when there are discrepancies between clinical 
symptoms and the laboratory value of testosterone. 
Few laboratories measure free testosterone, and a 
common practice is to calculate free testosterone 
using algori thms avai lable on the internet .  A 
recent publication draws attention to the potential 
inaccuracies of these calculations.  Measurement of 
total testosterone, the formulae used to calculate free 
testosterone and, to a lesser extent, measurement 
of sex hormone-binding globulin, are potential 
sources of inaccuracies [33].  There are no generally 
accepted lower limits of normal for free testosterone 
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for the diagnosis of hypogonadism. However, a free 
testosterone level below 225 pmol L-1 (65 pg mL-1) can 
provide supportive evidence for testosterone treatment 
[31]. Threshold values for bioavailable testosterone 
depend on the method used and are not generally 
available.  Equilibrium dialysis is the gold standard for 
free testosterone measurement.  Free testosterone assays 
based on analog displacement immunoassays are widely 
available but do not give an accurate measurement of 
free testosterone; thus they should not be used [31]. 
Alternately, measuring serum SHBG levels together 
with reliable serum total testosterone levels provides 
the data necessary for calculating free testosterone 
levels.  Calculated free testosterone correlates well 
with free testosterone by equilibrium dialysis [31]. 
Efforts to create standardization of testosterone assays, 
agreement on standards for testosterone measurement 
and accurate reference ranges for testosterone by 
liquid chromatography–mass spectrometry (LC–MS)/
MS are being developed.  International reference 
standards, characterization of methodology, and 
population-based reference ranges for free testosterone 
by equilibrium dialysis are needed.  Consensus on the 
equilibrium constants for testosterone binding to SHBG 
and albumin will allow improved calculation of free 
testosterone [31].  Salivary testosterone has also been 
shown to be a reliable substitute for free testosterone 
measurements but cannot be recommended for general 
use at this time, since the methodology has not been 
standardized and adult male ranges are not available 
in most hospital or reference laboratories [31].  Again, 
only longer-term studies can resolve whether these 
methods of determining testosterone deficiency in 
elderly men have made contribution to their well-being. 
6				Benefits	of	testosterone	of	replacement	therapy
Restoring testosterone levels to within the normal 
range by using testosterone replacement therapy can 
improve many of the effects of hypogonadism.  In the 
past decade evidence has been produced of the benefit 
of androgen treatment on multiple target organs of 
hypogonadal men, and recent studies show short-term 
beneficial effects of testosterone in older men that are 
similar to those in younger men [34–37].
There may be beneficial effects on mood, energy 
levels and patients’ sense of well-being, sexual 
function, lean body mass (LBM) and muscle strength, 
erythropoiesis and BMD, cognition and some benefits 
on cardiovascular risk factors.  The following is a 
summary of studies examing the effects of testos terone 
replacement in mainly elderly men. 
6.1 Improving metabolic syndrome and diabetes type 2, 
cardiovascular disease
Many of the components of the metabolic syndrome 
(obesity, hypertension, dyslipidemia impaired glucose 
regulation, and insulin resistance) are also present 
in hypogonadal men.  Lower testosterone levels are 
associated with surrogate markers for cardiovascular 
disease, including less favorable carotid intima medial 
thickness [38] ankle/brachial index as a measure of 
peripheral arterial disease [39] and calcific aortic 
atheroma [40]. Endogenous testosterone concentrations 
are inversely related to mortality due to cardiovascular 
disease of all causes.  There is a positive correlation 
between serum testosterone levels and insulin 
sensitivity in men across the full spectrum of glucose 
tolerance [41] and an improvement of insulin sensitivity 
was noted after testosterone replacement.  The effects 
of testosterone administration on glycemic control of 
men with diabetes mellitus were until recently much 
less certain [42] but there are recent reports indicating 
a favorable effect of testosterone in addition to diet 
and exercise [43].  By increasing LBM and reducing 
fat mass, testosterone therapy modulates insulin 
resistance and risk of metabolic syndrome [42].  The 
mechanism of the fall in lipids might be related to the 
decrease in the visceral abdominal fat mass under the 
influence of androgens, which inhibit lipoprotein lipase 
activity and increase lipolysis [44], with improvement 
of insulin sensitivity and mobilization of triglycerides 
from abdominal fat tissue.  Low androgen levels are 
associated with an increased risk of cardiovascular 
disease in men. But data are lacking as to whether 
higher testosterone levels predict reduced incidence 
of combined nonfatal and fatal major cardiovascular 
events [45].  The inverse correlation between T levels 
and the severity of coronary artery disease [46] may 
be related to the fact that low androgen levels are 
accompanied by an accumulation of abdominal visceral 
fat [47, 48] associated with  increased cardiovascular 
risk factors, impaired glucose tolerance, and non-insulin-
dependent diabetes mellitus  [49].
Testosterone replacement therapy does not increase 
the incidence of cardiovascular disease or events such 
as myocardial infarction, stroke, or angina [50].  A 
meta-analysis [51] in 2007 concluded that the current 
Androgens: efficacy and safety in elderly men 
Louis J Gooren
http://www.asiaandro.com;  aja@sibs.ac.cn  |  Asian Journal of Andrology
141
npg
available evidence shows no association between 
testosterone replacement therapy and cardiac events. 
However, trials of testosterone therapy generally 
have not been designed or adequately powered to 
detect effects on clinically significant cardiovascular 
events [52].  The outcome of most studies in men 
report either a favorable or neutral effect of normal 
testosterone levels on cardiovascular disease in men. 
The administration of testosterone in physiological 
concentration increases coronary blood flow in patients 
with coronary heart  disease [53].  Beneficial effects 
on endothelial function [54] and myocardial ischemia 
have also been demonstrated [46, 55, 56] but not on 
cardiovascular mortality [53, 54].  Thus, although 
lower testosterone levels are associated with higher 
cardiovascular risk and to an extent with mortality in 
aging men, randomized controlled clinical trials of 
adequate size and duration are needed to determine 
whether testosterone therapy will reduce morbidity and 
mortality from cardiovascular disease in hypogonadal 
or eugonadal men.
6.2 BMD
Osteopenia, osteoporosis, and  fracture prevalence 
rates are greater in hypogonadal younger and older men 
[57].  The prevalence of osteoporosis in testosterone 
deficient males is double that of those with normal 
testosterone level [58].  Testosterone plays a major role 
in BMD [59].  Bone density in hypogonadal men of all 
ages increases under testosterone substitution provided 
the dose is high enough [60, 61], although normal adult 
bone mass is not reached [62].  Testosterone produces 
this effect by increasing osteoblastic activity and 
through aromatization to estrogen reducing osteoclastic 
activity.  Part of the androgen effects on bone are at 
least partially indirect, mediated via their aromatization 
product estradiol [63, 64].  Patients with prostate cancer 
treated with androgen deprivation therapy have an 
increased risk of osteoporotic fracture.  The role of the 
LOH in aging males in bone fracture rate remains to be 
established [65].  The long-term benefit of testosterone 
requires further investigation. Trials of the effects of 
testosterone replacement therapy on BMD yielded 
mixed results.  The pooled results of a meta-analysis 
suggest a beneficial effect on lumbar spine bone density 
and equivocal findings on femoral neck BMD.  Trials 
of intramuscular testosterone reported significantly 
larger effects on lumbar bone density than trials of 
transdermal testosterone, particularly among patients 
receiving chronic glucocorticoids. None of studies have 
been large enough to show a fracture risk reduction 
with testosterone replacement therapy.
6.3 Muscle mass and strength
The aging process is accompanied by significant 
changes in body composition characterized by decreased 
fat free mass and increased and redistributed fat mass. 
These changes can impose functional limitations 
and increase morbidity [66, 67].  Maximal muscle 
strength correlates with muscle mass independently 
of age [68].  In men, declining testosterone levels 
that occur with aging can be a contributing factor 
to these changes by direct effect on muscle cells 
by testosterone or by stimulating IGF-1 expression 
directly and indirectly leading to increased muscle 
protein synthesis and growth [69].  Epidemiologic 
studies have demonstrated a correlation between 
bioavailable testosterone concentrations and fat-free 
mass [70]; however, the correlation with grip strength 
is not clear [70]. Testosterone replacement may be 
effective in reversing age-dependent body composition 
changes and associated morbidity [71]. Testosterone 
administration improves body composition: a decrease 
of fat mass, increase of LBM [37, 72, 73].  In most of 
these studies, the body weight change did not differ 
significantly. Testosterone therapy was associated  with 
a  greater improvement in grip strength than placebo 
[37, 74, 75].  A recent double-blind placebo-controlled 
study showed benefits of testosterone administration 
on skeletal muscle performance in elderly men with 
chronic heart failure [76], and another one found 
positive effects on the prevention of loss of muscle 
strength of the lower limbs [77].  Changes in lower-
extremity muscle strength and measures of physical 
function were reported in only a few studies and were 
inconsistent.  Recent cross-sectional studies showed 
that in aging men there are also positive correlations 
between testosterone and muscle strength parameters 
of upper and lower extremities, as measured by leg 
extensor strength and isometric hand grip strength 
[78].  Moreover, testosterone was positively associated 
with functional parameters, including the doors test as 
well as “get up and go” test, and 5-chair sit/stand test 
[79].  By contrast, some studies have found an increase 
in LBM but no change in physical function [80] or 
an increase in strength of knee extension or flexion. 
Although there is a potential role of testosterone in 
the management of frailty, it is not known whether 
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testosterone replacement improves physical function 
and other health-related outcomes, or reduces the risk 
of disability, falls, or fractures in older men with low 
testosterone levels [81].
6.4 Improved sexual desire, function and performance
The prevalence of ED increases markedly with age 
[82, 83].  Serum-free testosterone was significantly 
correlated with erectile and orgasmic function domains 
of the International Index of Erectile Function (IIEF) 
questionnaire.  Compared with younger men, elderly 
men require higher levels of circulating testosterone 
for libido and erectile function [84, 85].  However, and/
or diminished libido with or without a testosterone 
deficiency, might be related to other co-morbidities or 
medications [86].
Men with ED and/or diminished libido and documented 
testosterone deficiency are candidates for testosterone 
therapy.  Adequate testosterone treatment can restore 
venous leakage in the corpus cavernosum which is a 
frequent etiological factor in ED in elderly men [87]. 
Overviews of randomized controlled clinical trials 
indicate some benefit of testosterone therapy on sexual 
health-related outcomes [88].  Long-term follow-up of 
testosterone replacement in hypogonadal males and a 
control group indicates that self-assessment of libido 
was significantly higher in the testosterone-treated 
group [50].  Testosterone replacement has also been 
shown to enhance libido and the frequency of sexual 
acts and sleep-related erections [75, 89].
Transdermal testosterone replacement therapy, 
in particular, has  been linked to positive effects 
on fatigue, mood, and sexual function, as well as 
significant increases in sexual activity [90].  In the 
presence of a clinical picture of testosterone deficiency 
and borderline serum testosterone levels, a short 
therapeutic trial may be tried.  There is evidence that 
the combined use of testosterone and PDE5 inhibitors 
in hypogonadal or borderline eugonadal men have 
a synergetic effect [45, 91–93].  The combination 
treatment should be considered in hypogonadal patients 
with ED failing to respond to either treatment alone. 
Testosterone produces this effect by enhancing the 
production of nitric oxide synthase. 
6.5 Lower urinary tract symptoms
In addition to improvement in sexual function, 
testosterone therapy may also improve lower urinary 
tract symptomatology/bladder functions by increasing 
bladder capacity and compliance and decreasing detrusor 
pressure at maximal flow in men with LOH [11, 94]. 
6.6 Mood and energy and quality of life (QoL)
Men older than 50 years with low free testosterone 
levels had poorer QoL. Hypogonadal men commonly 
complain of loss of libido, dysphoria, fatigue, and 
irritability [95, 96].  These symptoms overlap with 
signs and symptoms of major depression.  There is 
significant inverse correlation between bioavailable 
testosterone levels (but not with total testosterone) 
and a depression score in elderly men, independent of 
age and weight [97].  There was a reduced libido and 
reduced feelings of well being and minimal effect on 
mood in patients with induced testosterone deficiency; 
the depressive symptoms during the hypogonadal 
state were reversed by testosterone replacement 
[98].  Testosterone replacement therapy has variable 
effects on mood, energy and sense of well being.  The 
results of placebo-controlled randomized trials on 
testosterone’s effect on QoL and depressive mood 
were inconsistent across trials and imprecise [99, 100]. 
Testosterone administered to nondepressed eugonadal 
men at physiological doses, did not result in significant 
effects on mood [101, 102].  In hypogonadal men, 
testosterone replacement was associated with improved 
mood and well-being, and reduced fatigue and 
irritability [103–105].  Randomized controlled trials of 
testosterone therapy in men without or with underlying 
chronic i l lness using a variety of testosterone 
formulations, report equivocal improvements in QoL 
measures, including general well-being and fatigue 
[106, 107].  For patients with major depression 
and/or dysthymia, improvement was equal to that 
achieved with standard antidepressants with significant 
improvement in the depression inventory score.  This 
effect may be a direct effect of testosterone or related 
to positive effects of testosterone on weight and/or 
other anthropometric indices.  Additional studies are 
needed to assess the effects of testosterone on clinical 
depression indices in human immunodeficiency virus-
infected patients [108, 109].  No relationship between 
testosterone level and depressive symptoms was 
found in the Massachusetts Male Aging Study.  This 
discrepancy in the results of the effects of  testosterone 
replacement therapy on mood may be explained by 
the genetic polymorphism in the androgen receptor 
which defines a vulnerable group in whom depression 
is expressed when testosterone levels fall below a 
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particular threshold [110, 111].
6.7 Cognitive function
Age-related decreases in bioavailable testosterone 
predicted age-related decline in visual and verbal 
memory.  There is good evidence for a strong correlation 
between testosterone levels and cognitive performance, 
such as spatial abilities or mathematical reasoning. 
Higher bioavailable and free testosterone concentrations 
have each been associated with better performance in 
specific aspects of memory and cognitive function, with 
optimal processing capacity found in men ranging from 
35 to 90 years of age, even after adjustment for potential 
confounders including age, educational attainment and 
cardiovascular morbidity [112, 113].  whereas total 
testosterone was not [114].  However, contradictory 
findings have also been reported.  In men undergoing 
hormonal therapy for prostate cancer, suppression of 
endogenous testosterone synthesis and blockade of 
the androgen receptor resulted in a beneficial effect on 
verbal memory but an adverse effect on spatial ability 
[115] and visuomotor showing a slowed reaction times 
in several attentional domains.  While the outcome 
of these studies looks promising, there is as yet no 
definitive proof of the beneficial effects of restoring 
testosterone levels to normal in elderly men on clinical 
parameters.  Trials of testosterone therapy in men to 
evaluate its effects on measures of cognitive function 
and memory to date were all relatively small and of a 
relatively short duration and have shown mixed results 
[116, 117].  Transdermal testosterone treatment in 
men aged 34 to 70 years improved verbal memory and 
spatial memory respectively [118] and intramuscular 
testosterone improved verbal and spatial memory  and 
constructional abilities in non-hypogonadal men with 
mild cognitive impairment and Alzheimer’s disease 
[119].  In one study of healthy men aged 50 to 90 years, 
intramuscular testosterone alone or in combination with 
the aromatase inhibitor anastrozole improved spatial 
memory, whereas verbal memory only improved in 
testosterone-treated men in the absence of anastrozole, 
raising the possibility that part of the effect of exogenous 
testosterone is mediated by its aromatization to estradiol 
[119].  Although the evidence from observational 
studies is not uniform, lower free testosterone appears 
to be associated with poorer outcomes on measures 
of cognitive function, particularly in older men and 
testosterone therapy in hypogonadal men may have 
some benefit for cognitive performance.
6.8 Improving anemia
Endogenous androgens are known to stimulate 
erythropoiesis; increase reticulocyte count, blood 
hemoglobin levels and bone marrow erythropoietic 
activity in mammals, whereas castration has opposite 
effects.  Testosterone deficiency results in a 10% to 20% 
decrease in the blood hemoglobin concentration, which 
can result in anemia [120, 121].  Young hypogonadal 
men usually have fewer red blood cells and lower 
hemoglobin levels than age-matched controls, whilst 
healthy older men also may have lower hemoglobin 
than normal young men. 
7 Safety of testosterone administration to elderly 
men 
The progressive decline of testosterone in aging 
men is supported by scientific evidence [1, 3].  Whether 
older hypogonadal men will benefit from testosterone 
treatment and what will be the risks associated with 
such intervention can only be resolved by sufficiently 
powered studies.  Data on the risks of testosterone 
administration are needed, particularly on its safety 
in elderly men [31, 122].  It is unlikely that rigorous 
scientific data with regard to safety of testosterone 
administration to elderly men will become available 
soon.  Such studies would include 5 000–7 000 men 
and would require 5–7 years of observation.  So, for the 
time being, smaller scale studies will have to be utilized 
to garner information on safety.  The main side effects 
of testosterone administration are listed below. 
7.1 Polycythemia 
There is curvilinear relationship in men (not 
receiving testosterone administration) between plasma 
testosterone levels and hemoglobin [22].  Testosterone 
exerts its effect on erythropoiesis through a number 
of mechanisms.  Testosterone has an effect on 
erythropoietin production in the kidney [123] but it has 
also a direct effect on colony formation of progenitor 
cells of erythrocytes [124].  In a study by Wang [95], 
a dose dependent effect of testosterone could be 
established on hemoglobin and the hematocrit values. 
This dose-dependency was also apparent from another 
study [125], which compared the effects of transdermal 
versus intramuscular testosterone; the latter achieved 
higher plasma levels of testosterone and raised the 
hematocrit more than transdermal testosterone. In 
a recent study it was convincingly confirmed that 
Androgens: efficacy and safety in elderly men 
Louis J Gooren
Asian Journal of Andrology  |  http://www.asiaandro.com;  aja@sibs.ac.cn 
144
npg
testosterone has a dose-dependent stimulatory effect 
on hematopoiesis in men.  Remarkably, this effect was 
more pronounced in older men [121].  Also other studies 
confirmed the relevance of the dose of testosterone [126] 
and of age as factors in the stimulation of hematopoiesis 
[127].  Also obesity and shorter CAG repeats appeared 
to be factors [22]. 
A higher value of the hematocrit is associated with 
stroke [128, 129], and coronary heart disease [130]. 
However, a relation between increased hematocrit as 
a result of androgen supplementation as such and an 
increased risk for stroke or any cardiovascular event 
in general has not been demonstrated by a large meta-
analysis of placebo-controlled trials of testosterone 
administration to (elderly) men [131].  Polycythemia 
ia a manageable risk of androgen administration when 
hemoglobin levels and the hematocrit are monitored 
and the dose of testosterone is adjusted.
7.2 Lower urinary tract symptoms and prostate 
disease
Several follow-up studies of men receiving 
testosterone treatment [131–133] have failed to demon-
strate an exacerbation of voiding symptoms due to 
benign prostatic hyperplasia.  Complications such as 
urinary retention in therapy group did not occur at 
higher rates than in controls receiving placebo. 
The occurrence of prostate cancer after testosterone 
administration to (elderly) men has been reported [134–
138].  By contrast, a variety of studies, using various 
designs and testosterone formulations, over periods 
ranging from several months to 15 years, in men with 
a wide range of ages, have not revealed an increased 
risk of prostate cancer [139–154].  A meta-analysis 
found that testosterone treatment in older men compared 
to placebo was not associated with a significantly higher 
risk of detection of prostate cancer [131], although the 
frequency of prostate biopsies was much higher in the 
testosterone-treated group than in the placebo group [131]. 
The above applies also to the assessment of 
safety of testosterone administration to elderly men. 
There is no convincing evidence that testosterone is 
a main factor in the development of prostate cancer 
in elderly men and guidelines for monitoring have 
been developed which, if rigorously applied, render 
testosterone administration to elderly men acceptably 
safe therapy in men without a prior history of prostate 
carcinoma or without evidence of harboring a prostate 
carcinoma.  There are now at least three publications 
demonstrating a lack of prostate carcinoma recurrence 
with testosterone therapy after definitive prostate 
carcinoma treatment.  Two articles have reported no 
prostate-specific antigen (PSA) recurrence in a total of 
17 men, following radical prostatectomy in men with 
undetectable PSA [155, 156].  A third study reported 
that no cancer recurrence was noted in 31 hypogonadal 
men treated with brachytherapy with a follow-up of 
approximately 5 years [157].  These small studies 
suggest that normalization of testosterone in men 
who have shown no signs of recurrence of prostate 
cancer after treatment, could benefit from testosterone 
replacement.
The case of an 84-year-old man with hypogonadism, 
with biopsy-proven prostate cancer (Gleason 6 cancer 
in both lobes), treated with testosterone gel for 2 years 
has been reported.  In this man a decline of serum PSA 
was noted over the treatment period [158]. 
There is a consensus now that administration of 
testosterone to elderly men is a responsible practice 
provided certain guidelines of professional bodies are 
followed with regard to testosterone administration 
to elderly men [31, 122].  This consensus is based on 
expert opinion and there remains an urgent need for 
longer-term safety studies. 
7.3 Cardiovascular disease
Until a decade ago, it was a widely held belief that 
androgens have an atherogenic effect and thus led to 
cardiovascular disease, and androgen administration 
was regarded as adding to the risk of developing 
cardiovascular disease.  Over the last decade several 
papers have examined the relationship of androgens 
with cardiovascular disease and concluded that it is 
no longer tenable to regard testosterone as a culprit 
in the etiology of cardiovascular disease [159–163]. 
Recent epidemiological studies have found that 
low testosterone levels  are a predictor of mortality 
in elderly men [164–168].  Over the last 2 years a 
large number of review papers have highlighted the 
significance of depressed levels of testosterone and 
cardiovascular disease [4, 6, 169].
Studies of testosterone replacement in men have not 
reported problems with peripheral edema or exacerbation 
of hypertension or congestive heart failure, but because 
current data were largely collected from relatively 
healthy older men, the possible impact of fluid retention 
on chronically ill or more frail individuals should be 
considered.  Modest, usually transient, leg edema and 
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fluid retention (up to several kilograms in weight gain) 
is possible, especially within the first few months of 
testosterone replacement therapy [5]. 
7.4 Sleep apnea
Obstructive sleep apnea ayndrome (OSAS) is 
characterized by snoring, repetitive episodes of upper 
airway occlusion resulting in hypoxemia and sleep 
fragmentation and excessive daytime sleepiness [170]. 
OSAS is also associated with loss of libido and ED 
[171–172].  It has been estimated that 10% to 60% of 
patients with OSAS suffer from ED. 
Obesity, and more specifically, the metabolic 
syndrome is common in patients with OSAS [173, 
174].  OSAS is associated with an increased risk of 
hypertension, arrhythmia, myocardial infarction, stroke, 
and sudden death.  Sexual dysfunction associated 
with OSAS may also be explained by the metabolic 
syndrome [175, 176].  Men with OSAS have lowered 
plasma testosterone levels [177] but this association 
was largely explained by adiposity in agreement with 
the finding that the metabolic syndrome is associated 
with reduced plasma testosterone values [178, 175]. 
In a large meta-analysis of placebo-controlled trials of 
testosterone administration to (elderly) men [131], the 
frequency of sleep apnea was not significantly different 
between the two groups.  Nevertheless, it is safe to 
consider obstructive pulmonary disease in overweight 
persons or heavy smokers as a relative contra-indication.
8 Conclusion
There is a host of studies in elderly men with 
lower-than-normal testosterone reporting improvement 
of features of the metabolic syndrome, of BMD, of 
mood and of sexual functioning.  While the outcome 
of these studies looks promising, there is as yet no 
definitive proof of the beneficial effects of restoring 
testosterone levels to normal in elderly men on clinical 
parameters.  Few of these studies meet as yet rigorous 
standards of scientific enquiry: double-blind, placebo-
controlled design of the study.  The endpoints of the 
studies are usually surrogate markers of disease and not 
clinical endpoints such as improvement and prevention 
of cardiovascular disease, diabetes mellitus type 2, 
osteopenia/osteoporosis, less fractures and less frailty. 
Admittedly, studies to prove the latter are difficult to 
undertake in view of the costs and the long duration 
of such studies.  It is difficult to compare these studies 
because of the intrinsic difficulties in establishing 
the degree of hypogonadism in the various studies: 
laboratory outcomes may vary between laboratories and 
a certain laboratory value of testosterone does not mean 
the same for various men on the basis of properties of 
their androgen receptors. 
The above applies also to the assessment of safety 
of testosterone administration to elderly men.  There 
is convincing evidence that testosterone is not a main 
factor in the development of prostate cancer in elderly 
men and guidelines for monitoring have been developed 
which, if rigorously applied, render testosterone 
administration to elderly men acceptably safe. 
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